Who makes DPV-001 vaccine?

DPV-001 vaccine is developed by Bristol-Myers Squibb.

Last reviewed 2026-05-14 · How we verify

DPV-001 vaccine

Bristol-Myers Squibb · Phase 1 active Biologic

At a glance

Generic name	DPV-001 vaccine
Sponsor	Bristol-Myers Squibb
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC (PHASE1)
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread (PHASE1, PHASE2)
Pilot Study of DRibble Vaccine for Prostate Cancer Patients (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DPV-001 vaccine CI brief — competitive landscape report
DPV-001 vaccine updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI